Pre-made Ruplizumab benchmark antibody ( Whole mAb, anti-CD40LG therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-501
Anti-CD40LG therapeutic antibody (Pre-made Ruplizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD40LG therapeutic antibody (Pre-made Ruplizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||1i9r:HL:KM:XY|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus|